A set of 25 features of the nuclei is used in the classification of the biopsies by four different classifiers. The complete diagnostic procedure was tested on 737 microscopic images of fine needle biopsies obtained from patients and achieved 98.51% effectiveness. The results presented in this paper demonstrate selleck that a computerized medical diagnosis system based on our method would be effective, providing valuable, accurate diagnostic information.”
“BACKGROUND: Omega-3 fatty acids in free fatty acid form have enhanced bioavailability, and plasma levels are less influenced by food than for
ethyl ester forms.
OBJECTIVE: The aim was to evaluate the safety and lipid-altering efficacy in subjects with severe hypertriglyceridemia of an investigational
pharmaceutical omega-3 free fatty acid (OM3-FFA) containing eicosapentaenoic acid and docosahexaenoic acid.
METHODS: This was a multinational, selleck compound double-blind, randomized, out-patient study. Men and women with triglycerides (TGs )>= 500 mg/dL, but <2000 mg/dL, took control (olive oil [OO] 4 g/d; n = 99), OM3-FFA 2 g/d (plus OO 2 g/d; n = 100), OM3-FFA 3 g/d (plus OO 1 g/d; n = 101), or OM3-FFA 4 g/d (n = 99) capsules for 12 weeks in combination with the National Cholesterol Education Program Therapeutic Lifestyle Changes diet.
RESULTS: Fasting serum TGs changed from baseline by 25.9% (P <.01 vs OO), -25.5% (P <.01 vs 00), and -30.9% (P <.001 vs OO) with 2, 3, and 4 g/d OM3-FFA, respectively, compared with 4.3% with OO. Non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol-to-HDLC ratio, very low-density
lipoprotein cholesterol, remnant-like particle cholesterol, apolipoprotein CIII, lipoprotein-associated phospholipase KPT-8602 A(2), and arachidonic acid were significantly lowered (P <.05 at each OM3-FFA dosage vs OO); and plasma eicosapentaenoic acid and docosahexaenoic acid were significantly elevated (P <.001 at each OM3-FFA dosage vs OO). With OM3-FFA 2 and 4 g/d (but not 3 g/d), low-density lipoprotein cholesterol was significantly increased compared with OO (P <.05 vs OO). High-sensitivity C-reactive protein responses with OM3-FFA did not differ significantly from the OO response at any dosage. Fewer subjects reported any adverse event with OO vs OM3-FFA, but frequencies across dosage groups were similar. Discontinuation due to adverse event, primarily gastrointestinal, ranged from 5% to 7% across OM3-FFA dosage groups vs 0% for OO.”
“Aims To verify the relationship between enuresis in childhood and the type of urinary incontinence in adults, considering the gender and age. Methods In this retrospective cohort study the database used contained the records of patients who had with urinary complaints and underwent urodynamic studies in the period from 1999 to 2008. A multinomial logistic regression model was adjusted for the type of UI. Results A total of 661 patient records were analyzed, 585 (88.5%) women and 76 (11.